by FiveSenses | Jul 8, 2026 | News Release
Montreal, QC, Canada, July 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology,... 
by FiveSenses | Jun 17, 2026 | News Release
Montreal, QC, Canada, June 17th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO... 
by FiveSenses | Jun 3, 2026 | News Release
Montreal, QC, Canada, June 3rd, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John... 
by FiveSenses | Jun 1, 2026 | News Release
Montreal, QC, Canada, June 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John... 
by FiveSenses | Jun 1, 2026 | News Release
Montreal, QC, Canada, May 29th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today...
Recent Comments